The new 'COVID-19 smart patch' is the result of a collaboration between the Belgian companies Byteflies, Melexis, Quad Industries, Televic and Z-Plus and the Belgian departments of multinationals Henkel and Nitto. All partners provided expertise and technology components for the 15 cm long adhesive patch, which can easily applied to the left side of the chest. It has been developed especially for skin-friendly, medical use and contains high-tech electrodes and conductive inks to register vital signs. A ‘sensor dot’ located in the centre of the patch collects the patient’s vital signs and sends all the data to the cloud wirelessly. A mini temperature sensor will also be integrated soon. The healthcare centre’s nurses and the patient’s general practitioner or specialist can then access this cloud data on a user-friendly platform. Thus, the innovative patch can improve the patient follow-up at home and reduces time and effort for medical stuff in data management.
Led by veteran health care executive Mike Blue, the company’s non-invasive robotics platform and novel sonic beam therapy is awaiting full FDA clearance, but the company has already announced reams of promising new clinical and preclinical data, including successful human trials in Spain. In April of last year, HistoSonics closed a $54 million C-Round led by Varian Medical Systems, Inc, the global leader in radiation therapy and oncology solutions, and included Johnson & Johnson Innovation and the State of Wisconsin Investment Board, among others. Initially targeting liver and pancreatic cancer, HistoSonics’ Robotically Assisted Sonic Therapy (RASTSM) combines advanced robotics and imaging with a proprietary sensing technology to deliver personalized treatments with unparalleled precision and control. In layman’s terms, the tech uses sound energy to generate pressures strong enough to liquify and completely destroy targeted tissues at sub-cellular levels.